Meeting Coverage

A recent study evaluated the impact of circulating plasma cells in patients with primary multiple myeloma on bortezomib-containing induction therapy.

A recent study from ASH 2024 examined the clinical features and outcomes of RT in British Columbia, comparing two eras: the chemoimmunotherapy (CIT) era (pre-2016) and the novel agents (NA) era (post-2016).

Educational programs and psychological support addressing cancer-related beliefs and promoting healthier coping strategies are crucial for improving outcomes.

Molecular residual disease was detected about six months before radiographic confirmation of recurrence in patients with inflammatory breast cancer.

New research on breast cancer was presented at the San Antonio Breast Cancer Symposium 2024, including updates on HER2-enriched disease and lymphedema.

Will you be attending “Mind the Gap — Breast Cancer in the Young” at SABCS?

Treatment resistance and toxicity remain critical challenges in managing chronic lymphocytic leukemia (CLL), according to researchers at the ASH Annual Meeting.

Oral oncolytic therapies have revolutionized the treatment of chronic lymphocytic leukemia (CLL), offering improved outcomes and convenience for patients.

Will you be attending the morning symposia, “Addressing Current Questions and Controversies in the Management of Chronic Lymphocytic Leukemia – What Clinicians Want to Know” at ASH?

The 2024 ASHP Midyear Clinical Meeting will feature multiple medical specialties, including infectious disease, diabetes, oncology, pain management, and more.

Will you be attending “The Upside of Imposter Syndrome” on Thursday, December 12, at ASHP?

Addition of elotuzumab to standard therapy in transplant-eligible patients with MM did not improve PFS or OS in the long-term follow-up of the GMMG-HD6 trial.

“This study reveals distinct immune subpopulations associated with specific myeloma cell genotypes and highlights the central role of ncRNAs in modulating the phenotypic and functional states of both malignant and non-malignant cells in the MM BMME,” the authors concluded.

According to data from the 66th ASH Annual Meeting, advancements in the treatment of relapsed/refractory mantle cell lymphoma (R/R MCL) have introduced novel therapies such as BTK inhibitors.

While the findings affirm ibrutinib’s role in improving outcomes for patients from Brazil with CLL, they underscore the challenges of managing toxicities and late-line therapy.

Will you be attending “A Shifting Landscape: Treatment of MCL” on Monday, December 9 at ASH?